Stanford researchers introduced affordable gene-editing kits ready for the classroom, aiming to make the field more accessible for high school students.

We’re officially in the New Year, and though certain resolutions (read: finally signing up for that high-intensity workout ...

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...

FDA aligned on single-arm Phase 3 study to support potential accelerated and full approvalOn track to dose first patient in Phase 3 trial in ...

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market ...

AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal ...

Histamine intolerance is a proposed condition in which a person may have difficulty metabolizing histamine in food. Learn ...

This study presents a novel approach using metal-organic frameworks to enhance enzyme-electrode interactions, advancing ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

with a near-50% market share in both, supported by an enviable portfolio of patents and unmatched library of strains and enzyme classes.

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...